AUTOMEDICACIÓN CON ANÁLOGOS DEL GLP-1: RIESGOS CLÍNICOS Y EL PAPEL DEL FARMACÉUTICO EN EL USO RACIONAL
DOI:
https://doi.org/10.56238/arev8n4-040Palabras clave:
Análogos de GLP-1, Automedicación, Uso Irracional, Seguridad del Paciente, Atención FarmacéuticaResumen
Teniendo en cuenta el creciente uso de análogos del GLP-1 con fines estéticos y al margen de las indicaciones clínicas, resulta importante comprender los riesgos asociados a la automedicación y al uso irracional de estos medicamentos, ya que prácticas de este tipo pueden perjudicar a los pacientes. Este estudio tuvo como objetivo evaluar los principales riesgos relacionados con el uso de estos medicamentos, además de analizar el papel del farmacéutico en la promoción de un uso seguro y racional. Para ello, se llevó a cabo una revisión integradora de la bibliografía en bases de datos con criterios de selección previamente definidos. Se analizaron 22 artículos científicos, cuyos resultados revelaron que los efectos gastrointestinales son los más frecuentemente notificados por los usuarios, además de la aparición de acontecimientos adversos más graves, como cetoacidosis, pancreatitis y alteraciones neurológicas. También se pudo constatar que el seguimiento farmacéutico es fundamental, ya que contribuye a orientar a los pacientes, fomenta un uso seguro y ayuda a reducir las prácticas inadecuadas. Por último, aunque esta clase de medicamentos ofrece beneficios en el tratamiento de la obesidad, su uso sin la supervisión adecuada puede conllevar riesgos importantes, lo que refuerza la necesidad de realizar más estudios y de un seguimiento profesional para garantizar la seguridad a largo plazo.
Descargas
Referencias
ASHRAF, Amir Reza; MACKEY, Tim Ken; VIDA, Róbert György; et al. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. Journal of Medical Internet Research, v. 26, p. e65440, 2024.
BAYRAM-OZGUR, Dilara; DEMIRTÜRK, Ecenur; SAR, Yigitcan. Community Pharmacists’ Knowledge and Counseling Competence on GLP-1 Receptor Agonists in Obesity and Type 2 Diabetes Care in Türkiye: A Cross-Sectional Study. Diabetes, Metabolic Syndrome and Obesity, v. 19, p. 587750, 2026.
BODANOWITZ, Jonas Michael; MATTES, Isabell; LOEBERMANN, Micha; et al. Case Report: Rhabdomyolysis following initiation of tirzepatide. Frontiers in Pharmacology, v. 16, 2025.
CASELLA, Sarah; GALLI, Katelyn. Appendicitis: A Hidden Danger of GLP-1 Receptor Agonists? Journal of Pharmacy Technology, v. 40, n. 2, p. 108–111, 2024.
CHIAPPINI, Stefania; VICKERS-SMITH, Rachel; HARRIS, Daniel; et al. Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FAERS Pharmacovigilance Dataset. Pharmaceuticals, v. 16, n. 7, p. 994, 2023.
COLLINS, Logan; COSTELLO, Ryan A. Glucagon-Like Peptide-1 Receptor Agonists. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2026.
CROCETTA, Nicholas; GUAY, Kyle; WATSON, Alexandra. Evaluation of a pharmacist’s impact on the use of glucagon-like peptide-1 receptor agonists for weight management in a family medicine setting. Family Practice, v. 40, n. 2, p. 255–260, 2023.
DAI, Hao; LI, Yongqiu; LEE, Yao An; et al. GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity. JAMA Oncology, v. 11, n. 10, p. 1186–1193, 2025.
EUROPEAN MEDICINES AGENCY (EMA). Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8–11 July 2024. 2024.
EUROPEAN MEDICINES AGENCY (EMA). PRAC concludes that NAION is a very rare side effect of semaglutide medicines (Ozempic, Rybelsus, Wegovy). 2026.
FILIPPATOS, Theodosios D.; PANAGIOTOPOULOU, Thalia V.; ELISAF, Moses S. Adverse Effects of GLP-1 Receptor Agonists. Review of Diabetic Studies, v. 11, n. 3, p. 202–230, 2014.
GAW, Christopher E.; HAYS, Hannah L.; KEMP, Cydney A.; et al. Glucagon-Like Peptide-1 Receptor Agonist Cases Reported to United States Poison Centers, 2017–2022. Journal of Medical Toxicology, v. 20, n. 2, p. 193–204, 2024.
GUIRGUIS, A.; CHIAPPINI, S.; PAPANTI, G. D.; et al. Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments. European Neuropsychopharmacology, v. 82, p. 82–91, 2024.
IQBAL, Pathan Mohamad Rafe; MAADARANI, Ossama Sajeh; BITAR, Zouheir Ibrahim. Tirzepatide-induced ketoacidosis in non-diabetic patients. European Journal of Case Reports in Internal Medicine, v. 11, n. 4, 2024.
ISHØY, Pelle L.; KNOP, Filip K.; BROBERG, Brian V.; et al. Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia. Diabetes, Obesity and Metabolism, v. 19, n. 2, p. 162–171, 2017.
JADVANI, Rutvikkumar; SINGH, Meenu. From weight loss to muscle loss: rhabdomyolysis linked to semaglutide. Clinical Kidney Journal, v. 18, n. 12, p. sfaf356, 2025.
LUIZA, Vera Lucia; MENDES, Luiz Villarinho Pereira; TAVARES, Noemia Urruth Leão; et al. Inappropriate use of medicines and associated factors in Brazil. Health Policy and Planning, v. 34, n. Suppl 3, p. iii27–iii35, 2019.
MANDO, Nur; THOMSON, Erica; FOWLER, Matthew; et al. Acute Pancreatitis Caused by Tirzepatide. Cureus, v. 16, n. 12, p. e76007, 2024.
MASSY, Marine; MARTI, Stefanie; HAMMER, Helly; et al. Increased vision impairment reports linked to semaglutide. BMC Medicine, v. 23, p. 203, 2025.
MHRA (Medicines and Healthcare products Regulatory Agency). GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases. Drug Safety Update, 2026.
MODESTINO, Edward J.; BOWIRRAT, Abdalla; LEWANDROWSKI, Kai-Uwe; et al. Hemiplegic Migraines Exacerbated using an Injectable GLP-1 Agonist. Acta Scientific Neurology, v. 7, n. 5, p. 12–18, 2024.
MUSCHLER, Karen; MUSCHALEK, Rachael; HOYTE, Christopher. Characterization of GLP-1 agonist exposures reported to a poison center. Clinical Toxicology, v. 63, n. 2, p. 133–136, 2025.
ORGANIZAÇÃO PAN-AMERICANA DA SAÚDE (OPAS/OMS). OMS publica diretriz global sobre uso de medicamentos agonistas de GLP-1 para tratamento da obesidade. 2025.
OSEI, Samuel Prince; AKOMANING, Edwin; FLORUT, Teodora Francesca; et al. Gastrointestinal Safety Assessment of GLP-1 Receptor Agonists. Diagnostics, v. 14, n. 24, p. 2829, 2024.
PI-SUNYER, Xavier; ASTRUP, Arne; FUJIOKA, Ken; et al. A Randomized Controlled Trial of Liraglutide in Weight Management. New England Journal of Medicine, v. 373, n. 1, p. 11–22, 2015.
RODRIGUES, Marília Barreto; SILVA, Thiago Dos Santos Da; EMILIANO, William Da Silva, O uso off-label da semaglutida (Ozempic®) para emagrecimento e a atenção farmacêutica na dispensação, Brazilian Journal of Health Review , v. 1, pág. e76780, 2025.
SCAGLIUSI, Fernanda Baeza et al , O território desconhecido dos novos medicamentos para obesidade em usuários sem obesidade: uma perspectiva sociomédica, Obesity , p. oby.70069, 2025.
WILDING, John P. H.; BATTERHAM, Rachel L.; DAVIES, Melanie; et al. Weight regain after withdrawal of semaglutide. Diabetes, Obesity and Metabolism, v. 24, n. 8, p. 1553–1564, 2022.
ZHAO, Tao; ZHENG, Liting; FENG, Yiyun; et al. Association between semaglutide dosage forms and ocular adverse events. BMC Ophthalmology, v. 25, n. 1, p. 248, 2025.
ZHOU, Yu; CHEN, Mingyu; LIU, Libin; et al. Gastrointestinal risk associated with GLP-1 receptor agonists. Diabetes, Metabolic Syndrome and Obesity, v. 15, p. 155–163, 2022.
